Compare OSIS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSIS | ELVN |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 1997 | 2020 |
| Metric | OSIS | ELVN |
|---|---|---|
| Price | $203.00 | $46.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $302.83 | $43.40 |
| AVG Volume (30 Days) | 227.7K | ★ 1.0M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.76 | ★ 3.17 |
| EPS | ★ 8.95 | N/A |
| Revenue | ★ $1,089,286,000.00 | N/A |
| Revenue This Year | $9.74 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $22.44 | ★ N/A |
| Revenue Growth | ★ 13.35 | N/A |
| 52 Week Low | $186.50 | $14.79 |
| 52 Week High | $311.72 | $62.32 |
| Indicator | OSIS | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | N/A |
| Support Level | $196.30 | N/A |
| Resistance Level | $206.19 | N/A |
| Average True Range (ATR) | 5.83 | 0.00 |
| MACD | 0.41 | 0.00 |
| Stochastic Oscillator | 44.19 | 0.00 |
OSI Systems Inc is a designer and manufacturer of electronic systems and components for businesses in the homeland security, healthcare, defense, and aerospace markets. The firm is organized in three business segments: Security, which derives maximum revenue, provides security and inspection systems; Healthcare, which provides patient monitoring, diagnostic, cardiology, ventilation systems, and defibrillators; and Optoelectronics and Manufacturing, which provides specialized electronic components and manufacturing services for the Security and Healthcare segments and external original equipment manufacturers. The majority of the firm's revenue is generated in the United States, and the rest from Mexico, Europe, the Middle East and Africa, and the Asia Pacific regions.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.